Is CSL a buy going into 2014?

Melbourne-based biopharmaceutical company CSL (ASX: CSL) has seen its share price rally 23.2% this year, handily outperforming the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) which has increased by 9.8%. The return also beats some of its health sector peers including Sonic Healthcare (ASX: SHL) and Cochlear (ASX: COH) which have returned 19.4% and -28.5% so far this calendar year.

The share price gains were supported by impressive growth in both sales and earnings, with sales growing 7% on a constant currency basis and earnings per share increasing by 26% on a constant currency basis.

Other highlights reported in August when CSL released its full year results were a solid balance sheet with cash on hand of US$762 million and an 18% increase in the full year dividend, which actually led to a 27% gain for Australian shareholders thanks to a boost on currency conversion.

CSL’s underlying business continues to impress. The company continues to experience strong sales growth in a number of its product areas, as well as margin expansion which saw earnings before interest and tax margin grow from 26.6% to 29.1%, thanks to efficiency gains and a change in the sales mix across the product portfolio.

The outlook

The all-important outlook statement that companies generally provide with their full year results or at their Annual General Meeting (AGM) is followed closely by investors. At CSL’s AGM, management reported that for the first quarter of the current financial year the company was trading in line with expectations.  Importantly, management also provided guidance for a 10% increase in net profit after tax this financial year.

Foolish takeaway

The premium nature of CSL’s business model commands a premium valuation and CSL’s ongoing share buy-back will continue to support growth in earnings per share above profit growth. Given the outlook for double digit growth it’s likely that CSL’s share price will continue to be supported in 2014, however with a forecast price-to-earnings multiple of around 25 times, the stock is priced for perfection and the market would be unlikely to treat any hiccups with sympathy.

Would you like to improve your portfolio returns in 2014?

Interested in our #1 dividend-paying stock? Discover The Motley Fool's favourite income idea for 2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2014."

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.